Czech/SlovakiaCzech RepublicSlovakia

National platform to boost industrial biotechnology

16.07.2008

Brno – Czech biotechnologists and EU industry experts have worked out an action plan to improve the development of industrial biotechnology in the Czech Republic. The recommendations are based on three SWOT analyses (R&D, Innovation, and Policy) that monitor the current development stage of industrial biotechnology worked out at a two day roundtable that brought together Czech biotech experts with representatives from EuropaBio, SusChem, the EU-tech platform for sustainable chemistry, and the European Commission in Brno.

Enabling better tech transfer

“The Czech Republic had a great past in traditional biotechnology – in fermentation, continuous culture, or biotransformations. And it pioneered antibiotic production,” summarised Dr. Peter Sebo, biotechnologist at the Czech Academy of Sciences in Prague. “But currently, there are several bottlenecks that hamper the development of modern biotechnology.” Only four out of 42 modern biotech companies (Lonza, Baxter, Comtipor, ExBio) located in the Czech Republic are currently active in industrial biotech. Sebo estimates the industry in the Czech Republic as a whole employs about 2,000 staff and has turnover of roughly EUR200m per year, but added that there is limited R&D in advanced biotech, almost no biotech IP and thus no venture capital available. Nevertheless, he remained optimistic about the future. An Institute of Biotechnology was founded this January, while a biotech and biomed research centre called BIOCEV, which by 2012 will provide labs for 450 researchers and 150 students, is being built up in Prague. Last but not least, the government has established long term funding schemes for biotechnology. “Currently we have more funding than biotech people,” said Sebo.
On a national scale, the experts called for a specific funding program for white biotech that links national participants from industry and research, as well as for the launch of an awareness campaign for communicating the advantages of White Biotech to politicians and the public. They also re­commended improving technology transfer from research to industry, and educational programs to address the lack of managerial skills among researchers. Finally, they concluded that the construction of an open production plant would give Czech biotech companies the opportunity to test large-scale production without having to build costly production facilities on their own.
At the European level, they asked for a harmonisation of IP rights, additional funding for basic research projects, less bureaucracy, and the establishment of a European seed funding programme.
“The meeting has helped to better inform the Commission about industrial biotech, and map the possibility of further financial support tailored to the Czech specific situation,” said Michal Kostka, Deputy Director of the South Moravian Innovation Centre. The round table was the first in a series of meetings in which SusChem will be assessing White Biotech activities in eight Eastern EU member states.


Czech/SlovakiaCzech RepublicSlovakia

21.02.2009

Prague – At a meeting with Czech stakeholders in Prague in December, EuropaBio expressed its appreciation that the Czech Republic is one of the ‘pro-biotech’ EU member states. In January when the Czech Republic took over the...

Czech/SlovakiaCzech RepublicSlovakia

11.11.2008

Prague/Tokyo – Tokyo-based Otsuka Pharmaceutical has established its first research, development and manufacturing facility in Eastern Europe. By the end of August, the diversified company had completed the acquisition of Czech...

Czech/SlovakiaCzech RepublicSlovakia

22.08.2008

Prague – Czech scientists have appealed to the European Council not to to politicise the approval process for biotech crops. “Although the EU has the strictest rules on GM plants in the world, politicians in Brussels prefer to...

Czech/SlovakiaCzech RepublicSlovakia

20.05.2008

Bratisava – German Lanxess, specialist for the development, manufacture and distribution of specialty chemicals and intermediates, has opened a new sales company for Central/Eastern Europe in Bratislava. This is its 3rd...

Czech/SlovakiaCzech RepublicSlovakia

20.05.2008

Prague – Gate2biotech has released a report on what’s going on in biotechnology in the Czech Republic. Windows-users can download a free electronic copy of the company registry and academic landscape or order a hardcopy at:...

Czech/SlovakiaCzech RepublicSlovakia

19.03.2008

Prague – The worldwide clinical research organisation Icon plc (Dublin, Ireland) has further expanded its activities in Eastern Europe. The CRO opened offices in Prague (Czech Republic), Kiev (Ukraine), and Bucharest (Romania),...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Prague – The Czech Republic has increased its R&D expenditures significantly in the last year. At a1.88 billion, R&D investments rose by 18% compared to 2005, the second largest increase world-wide. Those expenditures achieved...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Kourim/Basel – Lonza Biotec s.r.o. (Kourim, Czech Republic), a specialist for microbial fermentation and manufacturing services, has completed the extension of its production plant in Kourim designed for the cGMP-compliant...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Prague – Prague Clinical Services s.r.o. will conduct the pivotal phase III trials in Europe for Gia­conda Ltd.’s (Sydney, Australia) lead product Myoconda®, an anti­biotic combination therapy for the treatment of MAP infection...

Czech/SlovakiaCzech RepublicSlovakia

24.09.2007

Prague/Norwood – The international clinical trial company Medpace Inc. (Norwood, USA) has acquired the Czech contract research organisation Monax s.r.o. (Prague) for an undisclosed sum. With the acquisition, which the firm...

Displaying results 21 to 30 out of 70

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-czech-slovakia/browse/2/article/national-platform-to-boost-industrial-biotechnology.html

Events

All Events

Stock list

All quotes

TOP

  • THERAMETRICS0.09 CHF12.50%
  • PAION2.99 EUR11.15%
  • CO.DON3.00 EUR5.63%

FLOP

  • 4SC1.09 EUR-6.03%
  • STRATEC BIOMEDICAL39.80 EUR-3.40%
  • ADDEX3.22 CHF-3.30%

TOP

  • SANTHERA91.65 CHF43.0%
  • CO.DON3.00 EUR26.1%
  • PAION2.99 EUR20.1%

FLOP

  • EVOTEC3.07 EUR-18.1%
  • 4SC1.09 EUR-18.0%
  • MEDIGENE4.06 EUR-14.0%

TOP

  • SANTHERA91.65 CHF2202.8%
  • CO.DON3.00 EUR244.8%
  • PAION2.99 EUR190.3%

FLOP

  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.58 EUR-41.1%
  • 4SC1.09 EUR-40.1%

No liability assumed, Date: 16.09.2014


Current issue

All issues

Product of the week

Products